Trial Information
Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders
Inclusion Criteria:
- Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
- Male or female of all ages
- Willing and able to sign informed consent
- Willing guardian consent for participants under 18 years of age
Exclusion Criteria:
- No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative
disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases
(MPD)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
The frequency of activating mutations of tyrosine kinases, and phosphatases in patients with acute leukemias (AL), lymphoproliferative disorders(LPD), myelodysplastic syndromes(MDS), and myeloproliferative disease(MPD)
Outcome Time Frame:
Duration of the study; Up to 5 years
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
IRB00004422
NCT ID:
NCT01728402
Start Date:
September 2008
Completion Date:
October 2013
Related Keywords:
- Acute Leukemia
- Lymphoproliferative Disorders
- Myeloproliferative Disorders
- Leukemia
- Lymphoproliferative Disorders
- Myeloproliferative Disorders
- Acute Disease
- Hematologic Neoplasms
Name | Location |
OHSU Knight Cancer Institute |
Portland, Oregon 97239 |